Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Bioharvest Sciences Inc. (BHST:NASDAQ), powered by AI.
Bioharvest Sciences Inc. is currently trading at $3.20. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Bioharvest Sciences Inc. on Alpha Lenz.
Bioharvest Sciences Inc.'s P/E ratio is -5.3.
“Bioharvest Sciences Inc. trades at a P/E of -5.3 (undervalued) with modest ROE of -83.2%. 3Y revenue CAGR of 84.5% highlights clear growth momentum.”
Ask for details →Bioharvest Sciences Inc. is a biotechnology company that focuses on developing innovative solutions for functional food and plant-based nutritional products. The company’s primary function is to harness the benefits of natural compounds using a proprietary biofarming technology that allows for the production of plant-derived nutrients on an industrial scale. This technology is notable for producing bioactive compounds without the need for complex plant cultivation processes, making it a sustainable and scalable approach to nutraceutical production. Bioharvest Sciences Inc. impacts several industries, including health and wellness, alternative medicine, and environmental sustainability sectors. By offering products that are rich in essential nutrients and antioxidants, the company caters to the growing consumer demand for healthier lifestyles and plant-based alternatives. As part of its market significance, Bioharvest stands out for its potential to transform agricultural practices and improve access to high-quality nutritive compounds globally, thus contributing to the advancement of the food and nutrition industries.
“Bioharvest Sciences Inc. trades at a P/E of -5.3 (undervalued) with modest ROE of -83.2%. 3Y revenue CAGR of 84.5% highlights clear growth momentum.”
Ask for details →Bioharvest Sciences Inc. (ticker: BHST) is a company listed on NASDAQ in the Consumer Defensive sector (Packaged Foods). Market cap is $59M.
The current price is $3.2 with a P/E ratio of -5.29x and P/B of 2.32x.
ROE is -83.17% and operating margin is -16.16%. Annual revenue is $35M.